Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in PGNMID
NCT07111338Phase 2Active, not recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jul 2025
- Primary completion
- May 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of telitacicept in proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID), sponsored by Peking University First Hospital. Primary endpoint: Change in 24-hour urine protein excretion at 24 weeks. Started Jul 2025; status: active, not recruiting.
02
Drugs
telitacicept
03
Conditions
proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID)
Beyond the preview
Go deeper on NCT07111338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07111338.